Welcome to Markets Desk, your midday read on what's moving markets and money.
Novo Nordisk took a hard hit Monday as investors walked away disappointed from the company's two thousand thirty strategic outlook. The Ozempic maker failed to deliver the kind of pipeline clarity or revenue trajectory the market was pricing in, and the selloff was swift — a reminder that in pharma, expectation management is half the battle.
Shifting to Berkshire Hathaway, Warren Buffett's announcement that he's stepping down as chairman continues to reverberate. The four words he offered investors as a farewell have been parsed endlessly, but the real story is what six decades of compounding discipline built — a return north of six million percent, rooted in patience, simplicity, and a refusal to chase noise.
And over at Treasury, Scott Bessent is facing serious pushback from top economists over his decision to deploy a bond buyback scheme as thirty-year yields approached near twenty-year highs. Critics, including his own mentor Stan Druckenmiller, argue this was not legitimate debt management — and more importantly, it showed the market exactly where Bessent's pressure point lies.
That's the tape. Markets Desk, signing off the floor.
